Federal Register of Legislation - Australian Government

Primary content

PB 37 of 2011 Determinations/Health as made
This instrument provides for changes to the conditions subject to which payments will be made by the Commonwealth in respect of the supply of pharmaceutical benefits by approved pharmacists and approved medical practitioners.
Administered by: Health
Registered 26 May 2011
Tabling HistoryDate
Tabled HR30-May-2011
Tabled Senate15-Jun-2011
Date of repeal 19 Mar 2014
Repealed by Health (Spent and Redundant Instruments) Repeal Regulation 2014

 

COMMONWEALTH OF AUSTRALIA

Instrument number PB 37 of 2011

Amendment determination under paragraph 98C(1)(b) of the National Health Act 1953

 

I, FELICITY McNEILL, Acting First Assistant Secretary, Pharmaceutical Benefits Division, Department of Health and Ageing, delegate of the Minister for Health and Ageing, make this instrument under paragraph 98C(1)(b) of the National Health Act 1953.

 

Dated   16 May 2011

 

 

 

 

 

 

FELICITY McNEILL

Acting First Assistant Secretary

Pharmaceutical Benefits Division

Department of Health and Ageing

Amendment determination — conditions

1              Commencement                                                        

                This instrument commences on 1 June 2011.

2              Amendment of the Determination under paragraph 98C(1)(b) of the National Health Act 1953 (PB 119 of 2008)

                Schedule 1 amends the Determination under paragraph 98C(1)(b) of the National Health Act 1953 (PB 119 of 2008).



Schedule 1            Amendments

 

[1]      Schedule 1, after entry for Mycophenolic Acid with Water – Purified BP

insert in the columns in the order indicated:

Phenoxymethylpenicillin with Water – Purified BP

Powder for oral liquid 125 mg (as potassium) per 5 mL, 100 mL

Powder for oral liquid 250 mg (as potassium) per 5 mL, 100 mL

[2]        Schedule 4, omit entry for Memantine

[3]        Schedule 4, entry for Risedronic Acid and Calcium

insert as next entry in the column headed “Form”:

 

Pack containing 4 enteric coated tablets risedronate sodium 35 mg and 24 tablets calcium 500 mg (as carbonate)

 [4]       Schedule 4, entry for Risedronic acid and calcium with colecalciferol

insert as next entry in the column headed “Form”:

 

Pack containing 4 enteric coated tablets risedronate sodium 35 mg and 24 sachets containing granules of calcium carbonate 2.5 g with colecalciferol 22 micrograms

 [5]       Schedule 4, omit entry for Sulfacetamide

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Note

All legislative instruments and compilations are registered on the Federal Register of Legislative Instruments kept under the Legislative Instruments Act 2003. 

See http://www.frli.gov.au.